Calcitonin for osteoporosis and bone pain

Area of Science:

• Endocrinology
• Pharmacology
• Orthopedics

Background:

• Calcitonin, particularly salmon calcitonin, has been a 25-year mainstay in treating osteoporosis and other bone turnover diseases.
• Clinical studies confirm calcitonin's efficacy in preserving bone mineral density (BMD) and reducing vertebral fracture risk.

Purpose of the Study:

• To review the established benefits of calcitonin in osteoporosis treatment.
• To explore the mechanisms beyond BMD increase contributing to its antifracture efficacy.
• To highlight calcitonin's unique analgesic properties and potential future applications.

Main Methods:

• Review of clinical studies and scientific literature on calcitonin's effects.
• Analysis of bone mineral density (BMD) changes and fracture risk reduction.
• Evaluation of calcitonin's impact on bone turnover and trabecular architecture.
• Assessment of calcitonin's analgesic effects in various bone pain conditions.

Main Results:

• Calcitonin preserves or increases BMD and reduces vertebral fractures in osteoporosis patients.
• Antifracture efficacy may stem from reduced bone turnover and preserved bone architecture, not solely BMD increases.
• Calcitonin provides significant pain relief for osteoporosis-related fractures, Paget's disease, and bone malignancies.

Conclusions:

• Calcitonin is a valuable therapeutic agent for osteoporosis, offering both bone-protective and pain-relieving benefits.
• Its mechanism involves improving bone quality and reducing bone turnover, alongside direct analgesic effects.
• Future developments, including new indications and oral administration, are expected to increase demand for calcitonin.